AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05814744 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound-guided intermediate Cervical Plexus Block Technique
Description: the injection of local anesthetic in intermediate cervical plexus nerve block is made between the investing layer of the deep cervical fascia and the prevertebral fascia. Following negative aspiration, 1-2 mL of local anesthetic is injected to confirm the proper injection site.
Study NCT05237804 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient component
Description: Video, booklet, website
Study NCT05237804 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Organisational component
Description: Coronarography, CT-scan, anesthesia...
Study NCT05761002 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: the Quadrivalent Vaccine (Gardasil)
Description: • Intralesional injection of the quadrivalent HPV vaccine (Gardasil) at a dose of 0.5ml, into the largest wart at 4-week intervals until complete clearance is achieved or for a maximum of three sessions.
Study NCT04997291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexrazoxane
Description: Twelve enrollees will be consecutively assigned to a dosing regimen of 400 mg/m2/dose. The medication will be administered in the operating room 30 minutes prior to starting cardiopulmonary bypass (dose #1), prior to aortic cross clamp removal (dose #2), and on the morning after surgery in the cardiac intensive care unit (dose #3).
Study NCT04773691 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active rTMS
Description: Two rTMS stimulation sessions spaced 15 minutes apart are delivered daily for 5 consecutive days.~A total of 10 sessions. Stimulation parameters: 10 Hz, 1000 pulses per session, 110% of SM, cortical target: right DLPFC
Study NCT04773691 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo rTMS
Description: Two rTMS stimulation sessions spaced 15 minutes apart are delivered daily for 5 consecutive days.~A total of 10 sessions. Stimulation parameters: delivering a non-significant current at the beginning and end of the stimulation, simulating active stimulation.
Study NCT04773691 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaires
Description: questionnaires for craving assessment: EVA, OCDS, CGI and ADS and signs of physical withdrawal by CIWA
Study NCT04773691 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: questionnaires for craving assessment: EVA, OCDS, CGI and ADS and signs of physical withdrawal by CIWA
Study NCT04773691 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Breathalyzer
Description: estimation of blood alcohol level
Study NCT04773691 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Breathalyzer
Description: estimation of blood alcohol level
Study NCT04983420 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: non-alcoholic Pilsner
Description: intake of 1 L non-alcoholic Pilsner per day for 2 weeks
Study NCT04983420 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: non-alcoholic wheat beer
Description: intake of 1 L non-alcoholic wheat beer per day for 2 weeks
Study NCT04983420 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: apple spritzer
Description: intake of 1 L apple spritzer per day for 2 weeks
Study NCT04983420 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: lemonade
Description: intake of 1 L lemonade per day for 2 weeks
Study NCT06317168 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Mean awake ambulatory BP measurements
Description: Results from all four arms will be compared to the mean awake ambulatory BP measured on the same arm and started immediately following completion of the testing protocol.
Study NCT00013013 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Systems Support
Study NCT05889637 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Gastric ultrasound
Description: Patient will be scanned first in the supine position and then in the right lateral decubitus position. The ultrasound probe will be placed in a sagittal plane in the epigastric region at the left subcostal margin and then will be moved past the midline in a fan like manner to the right subcostal region. Qualitative and quantitative assessments will be done.
Study NCT04440657 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Assured Parenting program
Description: Parents will receive parenting education for 10 weeks
Study NCT06479941 — intervention group
Intervention type: OTHER
Intervention: antibiotic treatment
Description: AT: Mother-infant cohort with antibiotic treatment group CS: Mother-infant cohort (Prophylactic antibiotics therapy) ND: Mother-infant cohort (Natural delivery)
Study NCT05677009 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: BUFEO system
Description: In the BUFEO Condition, the subject will receive oxygen through the BUFEO system.
Study NCT05677009 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: Standard Condition is the baseline apparatus utilized by the subject at the time of enrollment in the study. In the hospital setting, the supplemental oxygen delivery may come from compressed oxygen cylinders or liquid oxygen and is often delivered through a port in the facility wall at the bedside.
Study NCT05191108 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mindfulness stres reduction programe
Description: Complaints about PMS and sharing information about these complaints, Practice of breathing focused meditation, mplementation of mindful eating exercises,Raising awareness in daily activities,Teaching the body scanning exercise and repeating this practice during the week with the audio recordings given.Ensuring environmental awareness Ensuring that you live by being aware of the moments experienced during the week, 20 minutes of sitting breathing focused sitting meditation Coping with stress Sharing the experiences of the previous week Implementation of mindful vision practices Explaining the relationship between stress and experienced events.Eating exercises Mindful breathing Ensuring environmental awareness Explaining the importance of thinking about the relationship between stress and their reactions and accepting them without judgment, and sharing the experiences at the end of the day of silence.
Study NCT06526533 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Liberal Transfusion
Description: Liberal transfusion trigger group (patient receives RBC transfusion if Hb ≤ 90g/L).
Study NCT06526533 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Restrictive Transfusion
Description: Restrictive transfusion trigger group (patient receives RBC transfusion if Hb≤70g/L).
Study NCT06345911 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental group
Description: The animal characters were shown to the child before the bloodletting procedure. The child was asked to choose one of them and the one chosen by the child was attached to the vacutainer. The child and their parents were taken to the blood collection room. During the bloodletting procedure, the child was asked to focus on the animal character they had chosen.
Study NCT05296005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Given PO
Study NCT05296005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Given IV
Study NCT05296005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV
Study NCT05296005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Given IV
Study NCT05296005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given IV
Study NCT05296005 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiotherapy
Study NCT05296005 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Procedure
Description: Undergo surgical resection
Study NCT05181046 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nanodropper adaptor
Description: The Nanodropper adaptor is a sterile medical device that reduces the size of administered eyedrops by coupling to the original bottle.
Study NCT05181046 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Original eyedrop bottle/No Nanodropper
Description: The original eyedrop bottle dispenses standard eyedrops.
Study NCT06278480 — intervention group
Intervention type: DEVICE
Intervention: MegaCarti®
Description: Medical devices containing allogeneic cartilage
Study NCT06278480 — intervention group
Intervention type: PROCEDURE
Intervention: microfracture
Description: microfracture
Study NCT04640415 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Alarms
Description: Intervention consists of actively alerting staff personnel if physiologic vital signs, deviates from certain thresholds for more than a set duration. Continuous vital sign data will also be available to clinical staff.
Study NCT05531565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Litifilimab
Description: Administered as specified in the treatment arm.
Study NCT05531565 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as specified in the treatment arm.
Study NCT04552795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3TC
Description: 12 subjects will be administered 3TC, 300mg once daily, via an oral tablet for 24 weeks.
Study NCT05010265 — intervention group
Intervention type: OTHER
Intervention: Clinician Questionnaire
Description: Surveys will serve to identify preferences, expectations and concerns among clinicians and researchers surrounding data-sharing of uncertain diagnostic data generated through investigative neurotechnologies which will then be systematically evaluated.
Study NCT05010265 — intervention group
Intervention type: OTHER
Intervention: Semi Structured Interviews
Description: Semi-structured interviews will further serve to identify preferences, expectations and concerns among patients, surrogates, clinicians and researchers surrounding data-sharing of uncertain diagnostic data generated through these investigative neurotechnologies which will then be systematically evaluated.
Study NCT04851847 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Guided Tissue Regeneration (GTR)
Description: Use of resorbable collagen membrane to treat periodontal intrabony defects.
Study NCT04851847 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Guided Tissue Regeneration (GTR)
Description: Use of resorbable collagen membrane to treat periodontal intrabony defects.
Study NCT04893473 — intervention group
Intervention type: DEVICE
Intervention: IscAlert
Description: 3 IscAlert sensors in the limb undergoing surgery and two control sensors in the opposite limb are inserted and carbon dioxide is measured continuously.
Study NCT04843189 — intervention group
Intervention type: PROCEDURE
Intervention: Da Vinci Robotic Surgery
Description: Da Vinci Robotic Surgery
Study NCT06163768 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Insulin resistance
Description: Steps to conduct testing and treatment according to the approved regimen at Ho Chi Minh City University of Medicine and Pharmacy Hospital. The researcher did not intervene in the treatment process.
Study NCT05631873 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assistance with implementing Epic Smartlist
Description: A research assistant helps GI providers add a new SmartList in to patient letters in Epic EHR that auto populates the colonoscopy recommendation time interval in patient records
Study NCT05351866 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CBT-based mobile intervention for depression
Description: SparkRx is a 5-week program divided into levels intended to be completed weekly. SparkRx is a behavioral activation program. Participants are instructed to complete a weekly Patient Health Questionnaire (PHQ)-8 assessment and participant symptom check (PSC) in the mobile app. Tasks in the mobile app progress in a linear fashion (i.e., each task must be completed to progress to the next task).
Study NCT05351866 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mobile control with education about depression
Description: The control mobile application will consist of 5 weeks of educational content about depression. Participants will be instructed to complete a weekly Patient Health Questionnaire (PHQ)-8 assessment and PSC in the mobile app.
Study NCT06447402 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: 5 mL of normal saline will be nebulised in the control arm
Study NCT06447402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amphotericin B deoxycholate
Description: 2 mL of the above reconstituted amphotericin B solution will be obtained in a sterile syringe and transferred into the drug chamber of a nebulizer. Three mL of distilled water will be added to 2 mL of the reconstituted amphotericin B (5 mL liquid in the chamber ensures complete and easy nebulization of all the contents)
Study NCT06272110 — intervention group
Intervention type: OTHER
Intervention: System level Language Access (LA) intervention
Description: Culturally and linguistically appropriate and HL informed strategies and materials/toolkit for community members, patients, and health care providers and staff. Findings from the preparatory work and pre-implementation phase and discussions with key partners will inform the co-design of intervention strategies.
Study NCT05527431 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: high flow nasal cannula
Description: high flow nasal cannula
Study NCT05486611 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: W-GenZD Mobile Application
Description: W-GenZD is a mobile application program that delivers evidence-based therapy for the symptoms of mild-moderate depression and anxiety in adolescents in brief conversations with a fully automated relational agent called Woebot. It is a brief, self-guided 4 week-intervention that draws from cognitive behavioral therapy (CBT), interpersonal psychotherapy for adolescents (IPT-A), and elements of dialectical behavior therapy (DBT), depending on the presenting situation, to help the adolescent develop emotion regulation skills in the context of their everyday life. In this way, the mobile application is designed to be targeted, relevant, and integrated into the lived experience of adolescents, capable of delivering the appropriate technique for the problem at hand, at the time of need.
Study NCT05486611 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Digital Education Application (W-EdZD)
Description: Digital Education will be available to the participant via the 'Quest GenZ' smartphone application but will be devoid of active elements included in WB002. We will source this material from kidshealth.org, which is supported by Nemours Children's Health. We have received permission to use their content.~The materials are written at an 8th grade reading level and will include general health (e.g., food plate guide, caffeine, online safety, study skills) articles. A new article will be provided to the participant at a rate of once per week across the 4 weeks (4 articles total) and they will receive a weekly notification when a new article is available. Each article will be available for one week from release date.
Study NCT05527431 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: noninvasive ventilation
Description: noninvasive ventilation
Study NCT06361628 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: multicomponent intervention on vaccination awareness
Description: Educational sessions to create awareness on HPV and MMR (were addressed) vaccination that is culturally sensitive health information and provided in an easily understandable manner by trained health promoters (and healthcare professionals) to underserved communities. Support for navigation and access to vaccines.
Study NCT04262895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TTI-0102
Description: TTI-0102 is a cysteamine precursor.
Study NCT05641922 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BioTraceIO 360
Description: Use of the device for planning, monitoring and assessment of liver tissue ablations
Study NCT04262895 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT05038007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine
Description: As prior described
Study NCT05038007 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hydrochloride
Description: As prior described
Study NCT05278663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E6742
Description: E6742 tablet.
Study NCT05278663 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: E6742-matching placebo tablet.
Study NCT06566157 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prebiotic
Description: WellBiome® prebiotic complex: Inulin 67%, XOS 27%, Magnesium Chloride (MgCl2) 9.8 %
Study NCT06566157 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin (Corn)
Description: Placebo
Study NCT05744466 — intervention group
Intervention type: DRUG
Intervention: Deucravacitinib
Description: As prescribed by treating clinician
Study NCT05744466 — intervention group
Intervention type: DRUG
Intervention: Apremilast
Description: As prescribed by treating clinician
Study NCT05325333 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Retrieval-based word learning
Description: Learning sessions: Novel nouns and their meanings are practiced on Day 1. In both conditions, retrieval trials will initially be immediate. In the expanding condition, the next two retrieval trials will each occur after 1 intervening word and then after 3 intervening words for the remainder of the session. In the standard condition, all remaining retrieval trials will occur after 3 intervening words. This practice schedule is repeated the next day (Day 2).~Testing sessions: 5 minutes after the learning session on Day 2, the child is asked to recall each word and its meaning twice. One week after Day 1, this recall test is completed again. At this time, the child will complete a recognition test: viewing sets of 4 pictures, the child will hear each novel noun and point to its referent in the array.
Study NCT05942599 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cryopreserved BE CAR33 T Cells (BE752TBTTBCAR33PBL)
Description: Single-dose intravenous infusion (weight-based dosing) of a banded dose of CAR33+ T cells/kg. BECAR33 Total duration of treatment: 28 days follow up: 12 months
Study NCT04916808 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: DCISionRT Test
Description: The Prelude DCISionRT Test was developed by Prelude Corporation and is performed at its CLIA laboratory facility. The biomarkers used to evaluate the biologic signature of DCIS tissue are based on over a decade of research including the University of California, San Francisco, Yale University as well as Prelude Corporation. The test is prognostic for 10-year recurrence risk and predicts RT treatment benefit for invasive breast cancer. The laboratory is regulated under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity clinical testing and is accredited by the College of American Pathologists (CAP).
Study NCT04971720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacubitril-Valsartan 49 Mg-51 Mg Oral Tablet
Description: The subject will be randomized, in a double-blind manner to sacubitril/valsartan 49/51 mg once in the morning or once in the evening for a period of 28 days.
Study NCT04971720 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan 80 mg Oral Tablet
Description: The subject will be randomized, in a double-blind manner to valsartan 80 mg once in the morning or once in the evening for a period of 28 days.
Study NCT04731272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dulaglutide 0.75Mg/0.5Ml Inj Pen
Description: Randomized, open-label, cross-over study of 6 weeks exposure to dulaglutide 0.75 mg subcutaneous weekly or observation.
Study NCT04984668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GT90001+KN046
Description: GT90001 7.0mg/Kg， KN046 5mg/Kg
Study NCT04148742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DZD9008
Description: Daily dose of DZD9008, except for cycle 0 of Part A, in which a single dose of DZD9008 is administrated. Starting dose of DZD9008 is 50 mg once daily. If tolerated, subsequent cohorts will test increasing doses of DZD9008.
Study NCT05463016 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental Group 1: Color Correcting Lenses
Description: Color Correcting Lenses
Study NCT05463016 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Group 1: Placebo Lenses
Description: Placebo Lenses
Study NCT05463016 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Placebo Group 1 Crosses over to become Experimental Group 2: Color Correcting Lenses
Description: Color Correcting Lenses
Study NCT05463016 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Experimental Group 1 Crosses over to become Placebo Group 2: Placebo Lenses
Description: Placebo Lenses
Study NCT05463016 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Color Correcting Lenses in Subjects with Normal Color Vision
Description: Color Correcting Lenses
Study NCT04984668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GT90001+KN046
Description: GT90001 7.0mg/Kg ， KN046 3mg/Kg
Study NCT04984668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GT90001/KN046
Description: GT90001 4.5mg/Kg / KN046 5mg/Kg